Nabriva Therapeutics AG Financials

Nabriva Therapeutics Stock Summary

Nabriva Therapeutics competes with Evoke Pharma, and Clearside Biomedical. Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Nabriva Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Nabriva Therapeutics Key Financial Ratios

Nabriva Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Nabriva Therapeutics's current stock value. Our valuation model uses many indicators to compare Nabriva Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nabriva Therapeutics competition to find correlations between indicators driving Nabriva Therapeutics's intrinsic value. More Info.Nabriva Therapeutics AG is regarded third in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Nabriva Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.